The congestive heart failure treatment devices market size has grown strongly in recent years. It will grow from $21.07 billion in 2025 to $22.76 billion in 2026 at a compound annual growth rate (CAGR) of 8%. The growth in the historic period can be attributed to rising prevalence of congestive heart failure, increasing incidence of cardiovascular diseases, growth in implantable cardiac device usage, expansion of specialized cardiac care facilities, improved survival rates of heart failure patients.
The congestive heart failure treatment devices market size is expected to see strong growth in the next few years. It will grow to $30.07 billion in 2030 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to aging population with higher heart failure risk, increasing demand for minimally invasive cardiac therapies, growing focus on early intervention and disease management, expanding access to advanced heart failure treatment in emerging markets, rising adoption of long-term mechanical circulatory support devices. Major trends in the forecast period include rising adoption of advanced implantable heart failure devices, increasing use of ventricular assist devices in advanced chf, growing focus on reducing heart failure hospitalizations, expansion of device-based therapies for long-term heart support, increasing demand for continuous cardiac monitoring and management.
The increasing prevalence of cardiovascular disorders is expected to drive the growth of the congestive heart failure (CHF) treatment devices market in the coming years. Cardiovascular disorders include a wide range of diseases that affect the heart and blood vessels, such as coronary artery disease, hypertension, and heart failure, all of which impact blood circulation and overall heart health. This rise in cardiovascular conditions is largely attributed to growing risk factors like obesity, sedentary lifestyles, poor dietary habits, and aging populations. Congestive heart failure treatment devices play a vital role in managing these disorders by regulating heart rhythms and improving heart function, thereby significantly enhancing patient outcomes. For example, in October 2024, according to the Centers for Disease Control and Prevention, a US-based government agency, cardiovascular disease claimed 919,032 lives in 2023, representing one in every three deaths. Coronary heart disease remained the most common form of heart disease, and approximately one in six deaths from cardiovascular disease occurred among adults under the age of 65. As a result, the increasing prevalence of cardiovascular diseases is fueling the growth of the CHF treatment devices market.
Major companies operating in the congestive heart failure treatment devices market are concentrating on developing innovative solutions such as implant-free atrial septostomy systems to provide hemodynamic relief, reduce procedural complexity, and offer less invasive treatment options for heart failure patients. An implant-free atrial septostomy system is a minimally invasive device designed to create a controlled opening in the atrial septum without leaving a permanent implant, improving left atrial pressure and enhancing cardiac hemodynamics in heart failure patients. For example, in January 2025, Alleviant Medical Inc., a US-based medical device company, achieved significant FDA milestones for its novel no-implant interatrial shunt device for treating heart failure. The device offers a minimally invasive solution by creating a precise shunt that lowers elevated left atrial pressure without leaving a permanent implant. This approach reduces complications associated with implanted devices, ensures durable shunt patency, and improves symptoms, exercise capacity, and quality of life for chronic heart failure patients, providing a safer, innovative treatment option for those with limited alternatives.
In October 2024, Johnson & Johnson, a US-based healthcare and medical technology company, completed the acquisition of V-Wave Ltd. for an undisclosed amount. With this acquisition, Johnson & Johnson seeks to enhance its cardiovascular portfolio by incorporating V-Wave’s innovative interatrial shunt technology, designed to lower left atrial pressure in patients with advanced heart failure. V-Wave Ltd. is an Israel-based medical device company that provides congestive heart failure treatment devices.
Major companies operating in the congestive heart failure treatment devices market are Medtronic plc, Abbott Laboratories, Boston Scientific Corporation, Biotronik SE & Co KG, LivaNova PLC, Berlin Heart GmbH, Jarvik Heart Inc, ReliantHeart Inc, Abiomed Inc, Lepu Medical Technology Co Ltd, Magenta Medical Ltd, MicroPort Inc, EBR Systems Inc, Syncardia Systems LLC, Oscor Inc, OSYPKA Medical GmbH, Calon Cardio‑Technology, CoreWave SA, Zoll Medical Corporation.
North America was the largest region in the congestive heart failure treatment devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the congestive heart failure treatment devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the congestive heart failure treatment devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the congestive heart failure treatment devices market by increasing costs for imported electronic components, medical-grade metals, and precision-engineered parts used in pacemakers, icds, crt devices, and vads. These cost pressures have particularly affected advanced implantable and ventricular assist device segments, with north america and europe experiencing higher exposure due to complex global supply chains. Increased tariffs have raised procurement costs for hospitals and specialized cardiovascular centers and influenced purchasing timelines. However, tariffs have also encouraged local manufacturing, supplier diversification, and regional production expansion, supporting long-term supply chain resilience.
The congestive heart failure treatment devices market research report is one of a series of new reports that provides congestive heart failure treatment devices market statistics, including congestive heart failure treatment devices industry global market size, regional shares, competitors with a congestive heart failure treatment devices market share, detailed congestive heart failure treatment devices market segments, market trends and opportunities, and any further data you may need to thrive in the congestive heart failure treatment devices industry. This congestive heart failure treatment devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
A congestive heart failure (CHF) treatment device is a medical tool created to assist in managing and addressing the effects of this condition, wherein the heart struggles to efficiently pump blood, resulting in fluid accumulation in the lungs and other tissues. Such devices play a role in monitoring, supporting, or enhancing heart function, thereby mitigating symptoms and reducing the likelihood of complications and hospitalizations associated with congestive heart failure.
The primary types of devices used in treating congestive heart failure encompass cardiac pacemakers, implantable cardioverter defibrillators (ICDs), cardiac resynchronization therapy (CRT) devices, counter-pulsation devices, and ventricular assist devices (VADs). A cardiac pacemaker, for example, is a small implant placed in the chest to regulate irregular heart rhythms by delivering electrical impulses to restore a normal heartbeat. These devices, including left ventricular assist devices (LVADs), right ventricular assist devices (RVADs), and biventricular assist devices (BIVADs), find utility across various settings, including hospitals, specialized cardiovascular treatment centers, and ambulatory surgery centers.
The congestive heart failure treatment device market consists of sales of external defibrillators, total artificial hearts (TAHs), implantable cardioverter defibrillators, and intra-aortic balloon pumps (IABPs). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The congestive heart failure treatment devices market size is expected to see strong growth in the next few years. It will grow to $30.07 billion in 2030 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to aging population with higher heart failure risk, increasing demand for minimally invasive cardiac therapies, growing focus on early intervention and disease management, expanding access to advanced heart failure treatment in emerging markets, rising adoption of long-term mechanical circulatory support devices. Major trends in the forecast period include rising adoption of advanced implantable heart failure devices, increasing use of ventricular assist devices in advanced chf, growing focus on reducing heart failure hospitalizations, expansion of device-based therapies for long-term heart support, increasing demand for continuous cardiac monitoring and management.
The increasing prevalence of cardiovascular disorders is expected to drive the growth of the congestive heart failure (CHF) treatment devices market in the coming years. Cardiovascular disorders include a wide range of diseases that affect the heart and blood vessels, such as coronary artery disease, hypertension, and heart failure, all of which impact blood circulation and overall heart health. This rise in cardiovascular conditions is largely attributed to growing risk factors like obesity, sedentary lifestyles, poor dietary habits, and aging populations. Congestive heart failure treatment devices play a vital role in managing these disorders by regulating heart rhythms and improving heart function, thereby significantly enhancing patient outcomes. For example, in October 2024, according to the Centers for Disease Control and Prevention, a US-based government agency, cardiovascular disease claimed 919,032 lives in 2023, representing one in every three deaths. Coronary heart disease remained the most common form of heart disease, and approximately one in six deaths from cardiovascular disease occurred among adults under the age of 65. As a result, the increasing prevalence of cardiovascular diseases is fueling the growth of the CHF treatment devices market.
Major companies operating in the congestive heart failure treatment devices market are concentrating on developing innovative solutions such as implant-free atrial septostomy systems to provide hemodynamic relief, reduce procedural complexity, and offer less invasive treatment options for heart failure patients. An implant-free atrial septostomy system is a minimally invasive device designed to create a controlled opening in the atrial septum without leaving a permanent implant, improving left atrial pressure and enhancing cardiac hemodynamics in heart failure patients. For example, in January 2025, Alleviant Medical Inc., a US-based medical device company, achieved significant FDA milestones for its novel no-implant interatrial shunt device for treating heart failure. The device offers a minimally invasive solution by creating a precise shunt that lowers elevated left atrial pressure without leaving a permanent implant. This approach reduces complications associated with implanted devices, ensures durable shunt patency, and improves symptoms, exercise capacity, and quality of life for chronic heart failure patients, providing a safer, innovative treatment option for those with limited alternatives.
In October 2024, Johnson & Johnson, a US-based healthcare and medical technology company, completed the acquisition of V-Wave Ltd. for an undisclosed amount. With this acquisition, Johnson & Johnson seeks to enhance its cardiovascular portfolio by incorporating V-Wave’s innovative interatrial shunt technology, designed to lower left atrial pressure in patients with advanced heart failure. V-Wave Ltd. is an Israel-based medical device company that provides congestive heart failure treatment devices.
Major companies operating in the congestive heart failure treatment devices market are Medtronic plc, Abbott Laboratories, Boston Scientific Corporation, Biotronik SE & Co KG, LivaNova PLC, Berlin Heart GmbH, Jarvik Heart Inc, ReliantHeart Inc, Abiomed Inc, Lepu Medical Technology Co Ltd, Magenta Medical Ltd, MicroPort Inc, EBR Systems Inc, Syncardia Systems LLC, Oscor Inc, OSYPKA Medical GmbH, Calon Cardio‑Technology, CoreWave SA, Zoll Medical Corporation.
North America was the largest region in the congestive heart failure treatment devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the congestive heart failure treatment devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the congestive heart failure treatment devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the congestive heart failure treatment devices market by increasing costs for imported electronic components, medical-grade metals, and precision-engineered parts used in pacemakers, icds, crt devices, and vads. These cost pressures have particularly affected advanced implantable and ventricular assist device segments, with north america and europe experiencing higher exposure due to complex global supply chains. Increased tariffs have raised procurement costs for hospitals and specialized cardiovascular centers and influenced purchasing timelines. However, tariffs have also encouraged local manufacturing, supplier diversification, and regional production expansion, supporting long-term supply chain resilience.
The congestive heart failure treatment devices market research report is one of a series of new reports that provides congestive heart failure treatment devices market statistics, including congestive heart failure treatment devices industry global market size, regional shares, competitors with a congestive heart failure treatment devices market share, detailed congestive heart failure treatment devices market segments, market trends and opportunities, and any further data you may need to thrive in the congestive heart failure treatment devices industry. This congestive heart failure treatment devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
A congestive heart failure (CHF) treatment device is a medical tool created to assist in managing and addressing the effects of this condition, wherein the heart struggles to efficiently pump blood, resulting in fluid accumulation in the lungs and other tissues. Such devices play a role in monitoring, supporting, or enhancing heart function, thereby mitigating symptoms and reducing the likelihood of complications and hospitalizations associated with congestive heart failure.
The primary types of devices used in treating congestive heart failure encompass cardiac pacemakers, implantable cardioverter defibrillators (ICDs), cardiac resynchronization therapy (CRT) devices, counter-pulsation devices, and ventricular assist devices (VADs). A cardiac pacemaker, for example, is a small implant placed in the chest to regulate irregular heart rhythms by delivering electrical impulses to restore a normal heartbeat. These devices, including left ventricular assist devices (LVADs), right ventricular assist devices (RVADs), and biventricular assist devices (BIVADs), find utility across various settings, including hospitals, specialized cardiovascular treatment centers, and ambulatory surgery centers.
The congestive heart failure treatment device market consists of sales of external defibrillators, total artificial hearts (TAHs), implantable cardioverter defibrillators, and intra-aortic balloon pumps (IABPs). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Congestive Heart Failure Treatment Devices Market Characteristics
3. Congestive Heart Failure Treatment Devices Market Supply Chain Analysis
4. Global Congestive Heart Failure Treatment Devices Market Trends and Strategies
5. Congestive Heart Failure Treatment Devices Market Analysis of End Use Industries
7. Global Congestive Heart Failure Treatment Devices Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Congestive Heart Failure Treatment Devices Total Addressable Market (TAM) Analysis for the Market
9. Congestive Heart Failure Treatment Devices Market Segmentation
10. Congestive Heart Failure Treatment Devices Market Regional and Country Analysis
11. Asia-Pacific Congestive Heart Failure Treatment Devices Market
12. China Congestive Heart Failure Treatment Devices Market
13. India Congestive Heart Failure Treatment Devices Market
14. Japan Congestive Heart Failure Treatment Devices Market
15. Australia Congestive Heart Failure Treatment Devices Market
16. Indonesia Congestive Heart Failure Treatment Devices Market
17. South Korea Congestive Heart Failure Treatment Devices Market
18. Taiwan Congestive Heart Failure Treatment Devices Market
19. South East Asia Congestive Heart Failure Treatment Devices Market
20. Western Europe Congestive Heart Failure Treatment Devices Market
21. UK Congestive Heart Failure Treatment Devices Market
22. Germany Congestive Heart Failure Treatment Devices Market
23. France Congestive Heart Failure Treatment Devices Market
24. Italy Congestive Heart Failure Treatment Devices Market
25. Spain Congestive Heart Failure Treatment Devices Market
26. Eastern Europe Congestive Heart Failure Treatment Devices Market
27. Russia Congestive Heart Failure Treatment Devices Market
28. North America Congestive Heart Failure Treatment Devices Market
29. USA Congestive Heart Failure Treatment Devices Market
30. Canada Congestive Heart Failure Treatment Devices Market
31. South America Congestive Heart Failure Treatment Devices Market
32. Brazil Congestive Heart Failure Treatment Devices Market
33. Middle East Congestive Heart Failure Treatment Devices Market
34. Africa Congestive Heart Failure Treatment Devices Market
36. Congestive Heart Failure Treatment Devices Market Competitive Landscape and Company Profiles
37. Congestive Heart Failure Treatment Devices Market Other Major and Innovative Companies
40. Congestive Heart Failure Treatment Devices Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Congestive Heart Failure Treatment Devices Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses congestive heart failure treatment devices market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for congestive heart failure treatment devices? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The congestive heart failure treatment devices market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product: Cardiac Pacemaker; Implantable Cardioverter Defibrillators (ICDs); Cardiac Resynchronization Therapy Devices (CRT); Counter Pulsation Devices; Ventricular Assist Devices (VADs)2) By Application: Left Ventricular Assist Device (LVAD); Right Ventricular Assist Device (RVAD); Biventricular Assist Device (BIVAD)
3) By End-User: Hospitals And Clinic; Specialized Cardiovascular Disease Treatment Centers; Ambulatory Surgery Centers
Subsegments:
1) By Cardiac Pacemaker: Single Chamber Pacemaker; Dual Chamber Pacemaker; Biventricular Pacemaker2) By Implantable Cardioverter Defibrillators (ICDs): Traditional ICDs; Subcutaneous ICDs; CRT-D (Cardiac Resynchronization Therapy Defibrillator)
3) By Cardiac Resynchronization Therapy Devices (CRT): CRT-P (Cardiac Resynchronization Therapy Pacemaker); CRT-D (Cardiac Resynchronization Therapy Defibrillator)
4) By Counter Pulsation Devices: Intra-Aortic Balloon Pumps (IABP); External Counterpulsation Devices (ECP)
5) By Ventricular Assist Devices (VADs): Left Ventricular Assist Devices (LVAD); Right Ventricular Assist Devices (RVAD); Biventricular Assist Devices (BiVAD)
Companies Mentioned: Medtronic plc; Abbott Laboratories; Boston Scientific Corporation; Biotronik SE & Co KG; LivaNova PLC; Berlin Heart GmbH; Jarvik Heart Inc; ReliantHeart Inc; Abiomed Inc; Lepu Medical Technology Co Ltd; Magenta Medical Ltd; MicroPort Inc; EBR Systems Inc; Syncardia Systems LLC; Oscor Inc; OSYPKA Medical GmbH; Calon Cardio‑Technology; CoreWave SA; Zoll Medical Corporation
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Congestive Heart Failure Treatment Devices market report include:- Medtronic plc
- Abbott Laboratories
- Boston Scientific Corporation
- Biotronik SE & Co KG
- LivaNova PLC
- Berlin Heart GmbH
- Jarvik Heart Inc
- ReliantHeart Inc
- Abiomed Inc
- Lepu Medical Technology Co Ltd
- Magenta Medical Ltd
- MicroPort Inc
- EBR Systems Inc
- Syncardia Systems LLC
- Oscor Inc
- OSYPKA Medical GmbH
- Calon Cardio‑Technology
- CoreWave SA
- Zoll Medical Corporation
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 22.76 Billion |
| Forecasted Market Value ( USD | $ 30.07 Billion |
| Compound Annual Growth Rate | 7.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 20 |
